Literature DB >> 28633253

Transforming Growth Factor Beta-2 Mutations in Barlow's Disease and Aortic Dilatation.

Kushtrim Disha1, Solveig Schulz2, Thomas Kuntze3, Evaldas Girdauskas4.   

Abstract

We report on a patient operated on for degenerative myxomatous mitral and tricuspid valve disease (Barlow's disease) and aortic root dilatation. A valve repair operation and the postoperative course were uneventful. Multigenerational genetic analyses revealed two different mutations in the transforming growth factor beta-2 gene in the same patient. The two mutations in different exons were inherited from both parents each. None of the parents presented with either valve dysfunction or aortic root dilatation. This rare case illustrates potentially common genetic and signaling pathways of concomitant myxomatous valve disease and aortic root dilatation.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28633253     DOI: 10.1016/j.athoracsur.2017.01.103

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.

Authors:  Mark A Oyama; Chad Elliott; Kerry A Loughran; Alexander P Kossar; Estibaliz Castillero; Robert J Levy; Giovanni Ferrari
Journal:  Cardiovasc Pathol       Date:  2020-01-07       Impact factor: 2.185

2.  TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism.

Authors:  Stefania Canè; Jacques Van Snick; Catherine Uyttenhove; Luc Pilotte; Benoit J Van den Eynde
Journal:  J Immunother Cancer       Date:  2021-02       Impact factor: 13.751

3.  Therapeutic targeting of TGF-β in cancer: hacking a master switch of immune suppression.

Authors:  Jitske van den Bulk; Noel F C C de Miranda; Peter Ten Dijke
Journal:  Clin Sci (Lond)       Date:  2021-01-15       Impact factor: 6.124

4.  Anti-TGF-β1 aptamer enhances therapeutic effect of tyrosine kinase inhibitor, gefitinib, on non-small cell lung cancer in xenograft model.

Authors:  Masaki Takahashi; Yoshifumi Hashimoto; Yoshikazu Nakamura
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-29       Impact factor: 10.183

5.  A novel TAB2 nonsense mutation (p.S149X) causing autosomal dominant congenital heart defects: a case report of a Chinese family.

Authors:  Jia Chen; Huizhen Yuan; Kang Xie; Xinrong Wang; Linglong Tan; Yongyi Zou; Yan Yang; Lu Pan; Junfang Xiao; Ge Chen; Yanqiu Liu
Journal:  BMC Cardiovasc Disord       Date:  2020-01-20       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.